I always though CART was a very dangerous procedure that had very little economic benefit. This is just CELG agreeing with me. If you look at CART, There can be some serious adverse reactions. When you remove blank T-cells and modify them and put them back into the body. There is high risk of the patient rejecting these cells or the cells actually attacking the wrong targets. I seen one fatality in a CART patient that turned fatal when these modified cells attacked the patients healthy cells in the heart.
Thanks again. Interesting stuff. 65% currently in cash was interesting also.
CELG is wreaking havoc, avoid it like Ebola! I am playing Ultimate Stock Alerts (you’ll find them in Google). These guys know what they are doing.
Next year's p/e ratio is 18.25. $120 is a fair price for CELG without adjusting for the fact that it beats estimates by 20% consistently. Could add another 20% for that.
People do not keep stocks on hope. If people are not holding then it is because maybe the future is clouded with uncertainty. This stock over the last few months has been mostly down and bouncing in a trading range. This is not a stock for the faint of heart.
On June 10 -13, Celgene will present data on Otezla and CC-220. The big one here will be the data on CC-220. I had first estimated this drug could be worth up to 2B. This data will give us good info to see what kind of money this drug could earn. I think that could be a good catalyst to finally get Celgene out of this rut.
60% cash as of end of May.
I recently cashed out of BMRN and AMBA. I just couldn't justify their valuations to myself. I don't think their bad companies, but way too expensive for me anymore.
PS dividendseeker... Any chance I could get you to reveal the other 8? :-)
No harm in asking eh?
That is a good point. I never look at the past for a stock or company. All I care about is the future. Up to this point, CELG has been all about Revlimid. Now they are making the transition to a fully diversified biotech company across Hematology, Oncology, Immunology and Inflammatory. There is bound to be bumps in the road during this next phase of growth. As we see new drugs play out some will do better then hoped while others will probably disappoint. The key is to stay focused on the big picture and not get too caught up in the details.
Very helpful as usual dividendseeker. I appreciate you taking the time to send such a detailed analysis, as well as the thinking behind both your assessment and the approach you're taking (and have taken). Best of luck to you...
Good stuff trading_pro_broker. Thanks. I may go 50%/50%.